Donna H. Ryan, MD, FACP is a Professor Emerita at Pennington Biomedical in Baton Rouge, LA, where she had a 25-year career in clinical research in obesity. She was an Investigator on POUNDS Lost, Look AHEAD, DPP, DASH and other studies of the health benefits of weight loss by diet, lifestyle intervention and medications. Most recently, she was the co-Chair of the SELECT Steering Committee, the first cardiovascular outcome trial to demonstrate reduction with semaglutide in heart attack, stroke, and death in persons with obesity without diabetes. She has been an active member and former President of The Obesity Society and World Obesity Federation. She serves on Safety Monitoring Committees for three GLP-1 RA- related agents. She has more than 300 publications, is a frequent speaker on obesity and diabetes treatments and remains an active consultant and advisor to companies developing drugs, devices, lifestyle programs and medical approaches to obesity management.